en · de · es
selank-notes.peptides3626.com › News › Identity And Structural Background — Hands-On Walkthrough

Identity And Structural Background — Hands-On Walkthrough

By Editorial Desk · published 2026-06-28 · last reviewed 2026-08-01 · News

Everything below concerns Enkephalinase. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Structural Background

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Mechanism and Evidence Status

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideTuftsin analogue
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Calculated for the free peptide
Molecular weightAbout 751.9 g/molDerived from the sequence
AppearanceWhite to off-white powderTypical lyophilised form

Peptide Identity and Structure

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Related pages on this site

Origins and Proposed Mechanisms

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Selank Origin and Chemical Identity

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Background and Peptide Identity

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reference notes

=== Proton transfer reaction chamber === Proton transfer reaction mass spectrometry has traditionally used drift tubes as ion traps. However, radio frequency ion funnels offer an attractive alternative, as they improve compound specific sensitivity significantly. This is due to increasing the effective reaction time and focusing the ions. The same pressure ranges are required for ion funnels and drift tubes, so the technology is not difficult to implement. Ion funnels have been shown to favor transmission of ions with high m/z.

HLTV, formerly an initialism of Half-Life Television, is a news website and forum which covers professional Counter-Strike 2 esports news, tournaments and statistics. It is one of the leading websites within the Counter-Strike community with over 4 million unique visitors each month. In February 2020, the site was acquired by the sports betting group Better Collective.

In 1979 Zaffaroni was awarded the Chemical Pioneer Award by the American Institute of Chemists In 1995, he received the National Medal of Technology from President Bill Clinton for his contributions to the pharmaceutical and biotechnology industries. In 2004, he was one of the recipients of the Winthrop-Sears Medal from the Chemical Heritage Foundation and The Chemists’ Club, with George Rosenkranz. In 2005 he received the Bower Award for Business Leadership from the Franklin Institute for his creation of new biochemical processes and drug delivery technologies. In 2005 he was awarded the Gregory Pincus Award from the Worcester Foundation. In 2006, he received the Biotechnology Heritage Award, from the Biotechnology Industry Organization (BIO) and the Chemical Heritage Foundation.

Ibogaine is a psychoactive indole alkaloid derived from plants such as Tabernanthe iboga, characterized by hallucinogenic and oneirogenic effects. Ibogaine exhibits complex pharmacology by interacting with multiple neurotransmitter systems, notably affecting opioid, serotonin, sigma, NMDA, and nicotinic acetylcholine receptors; its metabolite noribogaine primarily acts as a serotonin reuptake inhibitor and κ-opioid receptor agonist. The psychoactivity of the root bark of the iboga tree, T. iboga, one of the plants from which ibogaine is extracted, was first discovered by forager tribes in Central Africa, who passed the knowledge to the Bwiti tribe of Gabon. It was first documented in the 19th century for its spiritual use, later isolated and synthesized for its psychoactive properties, briefly marketed in Europe as a stimulant, and ultimately controversially researched for its potential in treating addiction despite being classified as a controlled substance. Ibogaine can be semisynthetically produced from voacangine, with its total synthesis achieved in 1956 and its structure confirmed by X-ray crystallography in 1960. Its clinical use and development have been limited due to regulatory barriers and serious safety risks, such as toxicity to the heart. Ibogaine produces a two-phase experience—initially visionary and dream-like with vivid imagery and altered perception, followed by an introspective period marked by lingering side effects, such as nausea and mood disturbances, which may persist for days.

Vegemite ( VEJ-i-myte) is a thick, dark brown Australian food spread made from leftover brewers' yeast extract with various vegetable and spice additives. It was developed by Cyril Percy Callister in Melbourne, Victoria, in 1922. The Vegemite brand was owned by Mondelez International (formerly Kraft Foods Inc.) until January 2017, when it was acquired by the Australian Bega Cheese group in a US$460,000,000 (equivalent to about $604,000,000 in 2025) agreement for full Australian ownership after Bega would buy most of Mondelez International's Australia and New Zealand grocery and cheese business. A spread for sandwiches, toast, crumpets and cracker biscuits as well as a filling for pastries, Vegemite is similar to British Marmite, New Zealand Marmite, Australian Promite, MightyMite, AussieMite, OzEmite, Brazilian Cenovit, German Vitam-R and Swiss Cenovis. Vegemite is salty, slightly bitter, malty, and rich in glutamates giving it an umami flavour similar to beef bouillon. It is vegan, kosher and halal.

Sources: en.wikipedia.org

Reference notes

The Singapore government states that the death penalty is only used in the most serious of crimes, sending a strong message to potential offenders. They point out that in 1994 and 1999 the United Nations General Assembly failed to adopt United Nations resolutions calling for a moratorium on the death penalty worldwide, as a majority of countries opposed such a move. Singapore's permanent representative to the United Nations wrote a letter to the Special Rapporteur on extrajudicial, summary or arbitrary executions in 2001 which stated:

=== Sexual effects === From the available evidence, it seems men who have been circumcised with the aid of a circumcision device experience unchanged or heightened sexual pleasure and satisfaction. There is some evidence such men also derive long time improvements in erectile function. The accumulated data show circumcision has no adverse physiological effect on sexual pleasure, function, desire, or fertility. There is some evidence that circumcision has no effect on pain with intercourse, premature ejaculation, intravaginal ejaculation latency time, erectile dysfunction, or difficulties with orgasm. There are popular misconceptions that circumcision benefits or adversely affects the sexual pleasure of the circumcised person. According to a 2014 review, the effect of circumcision on sexual partners' experiences is unclear as it has not been well studied. According to a policy statement by the Canadian Paediatric Society that was reaffirmed in 2021, "medical studies do not support circumcision as having an impact on sexual function or satisfaction for partners of circumcised individuals".

The first refrigerated cars in Japan entered service in 1908, primarily for fish transport. They were of the ReSo 200 type, from 1909, followed by the ReSo 210 type, from 1912, and then the ReSo 230 type; all were reclassified into Re 1 type in 1928. Many of these cars were equipped with ice bunkers, but the bunkers were not generally used. Fish were packed in wooden or foam polystyrene boxes with crushed ice. Transporting fruit, vegetables, and meat in refrigerated rail cars was uncommon in Japan. For fruits and vegetables, ventilated cars were sufficient due to the relatively short distances involved. In contrast, meat, which requires low-temperature storage, was typically transported by ship, as most major Japanese cities are located along the coast. Refrigerator cars suffered heavy damage in World War II. After the war, the occupation forces confiscated many cars for their own use, using the ice bunkers as originally intended. Supplies were landed primarily at Yokohama, and reefer trains ran from the port to U.S. bases around Japan. Around this time, the surviving pre-war refrigerator cars were gradually retired and replaced with newer types. In 1966, JNR developed the ReSa 10000 and ReMuFu 10000 type refrigerated cars that could travel at 100 km/h (62 mph). They were used in fish freight express trains. "Tobiuo" (Flying fish) train from Shimonoseki to Tokyo, and "Ginrin" (Silver scale) train from Hakata to Tokyo, were operated. By the 1960s, refrigerator trucks had begun to displace railcars.

== People == Maxim (given name) Maxim (surname) Maxim (musician) Maxim., taxonomic author abbreviation of Karl Maximovich (1827–1891), Russian botanist Maksim, Metropolitan of all Rus, Metropolitan of Kiev (1283–1305) Maksim, Bulgarian Patriarch (1914–2012), Patriarch of the Bulgarian Orthodox Church Maksim, Serbian Patriarch (d. 1680), Patriarch of the Serbian Orthodox Church (1655-1674) Maksim Branković (d. 1516), Serbian Orthodox Metropolitan of Belgrade and Syrmia

Charles III returns to his public duties for the first time since his cancer diagnosis with a visit to University College Hospital's Macmillan Cancer Centre. He also becomes patron of Cancer Research UK. A bid by an Abu Dhabi based consortium to buy The Telegraph collapses, meaning the newspaper is for sale again.

Sources: en.wikipedia.org

Reference notes

== Nazi Resistance == The BRSD positioned itself squarely against National Socialism. It referred to Nazism as "pre-Christian, heathen destructive power' and criticized the ideological glorification of violence by the Nazis. As with other socialist organizations, the Federation was banned once the Nazis seized power, however, various members of the organization formed resistance groups, such as Erich Kürschner in Berlin.

=== Hemorrhage and trauma === Synthetic platelets have the potential to aid trauma care by rapidly enhancing hemostasis, reducing blood loss, and improving survival outcomes in hemorrhagic injuries. SynthoPlate, a liposome-based synthetic platelet surrogate, has been designed to mimic both platelet adhesion and aggregation mechanisms through heteromultivalent surface modifications. Studies have demonstrated that SynthoPlate maintains stability after sterilization via filtration and E-beam irradiation and remains viable during long-term suspension storage. In a porcine arterial injury model, a single intravenous dose of SynthoPlate resulted in 100% survival during the first hour post-injury, compared to 0% in saline-treated controls. Unlike unmodified liposomes, SynthoPlate was shown to enhance hemostasis while stabilizing mean arterial pressure, reducing blood loss, and improving survival outcomes. These findings suggest that platelet-mimicking nanoparticles could serve as a viable transfusion alternative for hemorrhage management in pre-hospital and battlefield settings. Peptide-based nanoparticles (pNPs) have been studied for their potential in hemorrhage control by mimicking natural clot formation. In vitro experiments demonstrated that pNPs, when incubated with CD105 and red blood cells, formed stable artificial clots with fibrous networks similar to natural thrombi. These clots resisted enzymatic degradation, maintaining structural integrity unlike natural fibrin clots.

=== Pharmacodynamics === Tandospirone acts as a potent and selective 5-HT1A receptor partial agonist, with a Ki affinity value of 27 ± 5 nM and approximately 55 to 85% intrinsic activity. It has relatively weak affinity for the 5-HT2A (1,300 ± 200), 5-HT2C (2,600 ± 60), α1-adrenergic (1,600 ± 80), α2-adrenergic (1,900 ± 400), D1 (41,000 ± 10,000), and D2 (1,700 ± 300) receptors, and is essentially inactive at the 5-HT1B, 5-HT1D, β-adrenergic, and muscarinic acetylcholine receptors, serotonin transporter, and benzodiazepine allosteric site of the GABAA receptor (all of which are > 100,000). There is evidence of tandospirone having low but significant antagonistic activity at the α2-adrenergic receptor through its active metabolite 1-(2-pyrimidinyl)piperazine (1-PP). Tandospirone has been found to produce antiaggressive effects in rodents. It has been found to increase oxytocin levels in rodents.

==== Maillard reaction ==== The Maillard reaction is a form of non-enzymatic browning involving an amino acid and a reducing sugar. The cellulose fibers of the shroud are coated with a thin carbohydrate layer of starch fractions, various sugars, and other impurities. The potential source for amines required for the reaction is a decomposing body, and no signs of decomposition have been found on the Shroud. Rogers also notes that their tests revealed that there were no proteins or bodily fluids on the image areas. Also, the image resolution and the uniform coloration of the linen resolution seem to be incompatible with a mechanism involving diffusion.

Of Molecules and Men (Prometheus Books, 2004; original edition 1967) ISBN 1-59102-185-5 Life Itself: Its Origin and Nature (Simon & Schuster, 1981) ISBN 0-671-25562-2 What Mad Pursuit: A Personal View of Scientific Discovery (Basic Books reprint edition, 1990) ISBN 0-465-09138-5 The Astonishing Hypothesis: The Scientific Search for the Soul (Scribner reprint edition, 1995) ISBN 0-684-80158-2 Georg Kreisel: a Few Personal Recollections. In: Kreiseliana: About and Around Georg Kreisel (1996), pp. 25–32. ISBN 1-56881-061-X

Sources: en.wikipedia.org

Frequently asked questions

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

How is it related to tuftsin?

Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.

Why do different sources use different names?

Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

Network